Release Date: Apr 2017
CC: PC, MK, PBL, SBP
Joshua Raizman, MSc, PhD, FCACB
Clinical Biochemist, Alberta Health Services, Edmonton, AB, Canada; Clinical Lecturer, University of Alberta, Edmonton, AB, Canada
This presentation will cover the newest technologies and tests available for accurate and sensitive detection of fetal aneuplodies. A general overview of maternal serum screening will be discussed followed by an introduction of non-invasive prenatal testing (NIPT). NIPT uses molecular biology methodology to detect fetal DNA in maternal blood. Studies show that its improved detection over traditional serum tests for detection of fetal anomalies can reduce unnecessary invasive procedures like amniocentiesis, which reduces mother/fetus harm and reduces costs. However, there are many obstacles to overcome before it can be fully and widely implemented.
After attending this session, participants will be able to:
· Describe how NIPT fits into current models of prenatal screening for fetal aneuploidies and biochemical testing.
· Identify the advantages and complexities of using NIPT in clinical practice.
· Assess the merits of NIPT and whether it can fully replace existing biochemical tests.
Who should attend? Practicing Pathologists, Residents, Doctoral Scientists, Laboratory Managers, Bench Supervisors, Bench Technologists & Technicians, Students